Blue Earth secures $28M in venture capital

By staff writers

July 23, 2015 -- Blue Earth Diagnostics has received $27.9 million (25.4 million euros) in capital from U.K. venture fund Syncona Partners.

The cash will allow the company to continue its regulatory approval preparations for F-18 fluciclovine, its investigational PET radiopharmaceutical for prostate and brain cancer. The company expects to submit applications to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use of the agent in prostate cancer patients experiencing biochemical recurrence.

Blue Earth Diagnostics has signed an agreement with Siemens Healthcare subsidiary PETNet Solutions to manufacture, distribute, and sell the agent in the U.S. once it has been approved, the company said.

Copyright © 2015

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking